# US 2017/0281778 A1 · Long-acting polymeric delivery systems

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281778 A1
- Document ID: US20170281778A1
- Status: Published application
- Kind: A1
- Application number: 15/621,782
- Filed: 2017-06-13
- Published: 2017-10-05
- Earliest claimed: 2014-04-21
- Assignees: Heron Therapeutics, Inc.
- Applicants: Heron Therapeutics, Inc.
- Inventors: Thomas B. Ottoboni; Lee Ann Lynn Girotti
- Web page: https://patentgrep.com/patent/US20170281778A1

## CPC

- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 23/00: Anaesthetics
- A61P 23/02: Local anaesthetics
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).

## Claims

### Claim 1

A composition, comprising: an amide-type local anesthetic, an enolic-acid non-steroidal anti-inflammatory drug (NSAID) and a delivery vehicle.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the amide-type local anesthetic is selected from the group consisting of bupivacaine, ropivacaine, levobupivacaine, dibucaine, mepivacaine, procaine, lidocaine, and tetracaine.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the enolic-acid NSAID is selected from the group consisting of meloxicam, piroxicam, tenoxicam, droxicam, lornoxicam, and isoxicam.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the amide-type local anesthetic is bupivacaine or ropivacaine and the enolic-acid NSAID is meloxicam.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the amide-type local anesthetic is present in the composition at between about 0.01 wt % and about 7.5 wt %.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the enolic-acid NSAID is present in an amount above about 0.01 wt % of the composition.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the delivery vehicle is a sustained-release delivery vehicle.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the sustained-release delivery vehicle is a polymeric formulation, a liposome, a microsphere, an implantable device or a non-polymeric formulation.

### Claim 9 (depends on 7)

The composition of claim 7, wherein the sustained-release delivery vehicle is a liposome selected from the group consisting of small unilamellar vesicles (SUV), large unilamellar vesicles (LUV), multi-lamellar vesicles (MLV) and multivesicular liposomes (MVL).

### Claim 10 (depends on 9)

The composition of claim 9, wherein the amide-type local anesthetic and the enolic-acid NSAID are entrapped in an aqueous space of the liposome or in a lipid layer of the liposome.

### Claim 11 (depends on 7)

The composition of claim 7, wherein the sustained-release delivery vehicle is a microsphere comprised of a bioerodible or biodegradable polymer.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the amide-type local anesthetic and the enolic-acid NSAID are entrapped in the microsphere.

### Claim 13 (depends on 8)

The composition of claim 8, wherein the implantable device is an osmotic pump with a reservoir comprising the amide-type local anesthetic and the enolic-acid NSAID.

### Claim 14 (depends on 7)

The composition of claim 7, wherein the sustained-release delivery vehicle is a non-polymeric formulation comprising sucrose acetate isobutyrate.

### Claim 15 (depends on 7)

The composition of claim 7, wherein the sustained-release delivery vehicle is a polymeric formulation in the form of a semi-solid polymer formulation comprising a polymer, the amide-type local anesthetic and the enolic-acid NSAID.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the polymer is a bioerodible or biodegradable polymer.

### Claim 17 (depends on 15)

The composition of claim 15, wherein the polymer formulation forms an implant or depot in situ.

### Claim 18 (depends on 15)

The composition of claim 15, wherein the polymer is selected from the group consisting of polylactides, polyglycolides, poly(lactic-co-glycolic acid) copolymers, polycaprolactones, poly-3-hydroxybutyrates, and polyorthoesters.

### Claim 19 (depends on 15)

The composition of claim 15, wherein the polymer is a polyorthoester.

### Claim 20 (depends on 1)

The composition of claim 1, wherein the delivery vehicle is an aqueous solution.

### Claim 21 (depends on 1)

A method for managing pain in a subject in need thereof, comprising: administering to the subject a composition according to claim 1.

### Claim 22 (depends on 1)

A method for prophylactic treatment of pain in a subject, comprising: administering to the subject a composition according to claim 1.

### Claim 23 (depends on 21)

The method of claim 21, wherein the administering is intramuscular, subcutaneous, perineural or to a wound.

### Claim 24 (depends on 23)

The method of claim 23, wherein the pain is acute pain or chronic pain.

### Claim 25

A semi-solid composition, comprising: a biodegradable polyorthoester, an amide-type local anesthetic, and an enolic-acid non-steroidal anti-inflammatory drug (NSAID).

### Claim 26 (depends on 25)

The composition of claim 25, wherein the amide-type local anesthetic is selected from the group consisting of bupivacaine, ropivacaine, levobupivacaine, dibucaine, mepivacaine, procaine, lidocaine, and tetracaine.

### Claim 27 (depends on 25)

The composition of claim 25, wherein amide-type local anesthetic is ropivacaine or bupivacaine.

### Claim 28 (depends on 25)

The composition of claim 25, wherein the enolic-acid NSAID is selected from the group consisting of meloxicam, piroxicam, tenoxicam, droxicam, lornoxicam, and isoxicam.

### Claim 29 (depends on 25)

The composition of claim 25, wherein the enolic-acid NSAID is meloxicam.

### Claim 30 (depends on 25)

The composition of claim 25, wherein the amide-type local anesthetic is present in the composition at between about 0.01 wt % and about 7.5 wt %.

### Claim 31 (depends on 25)

The composition of claim 25, wherein the enolic-acid NSAID is present in an amount above about 0.01 wt % of the composition.

### Claim 32 (depends on 25)

The composition of claim 25, wherein the polyorthoester comprised in the composition is selected from the polyorthoesters represented by Formulas I, II, III and IV.

### Claim 33 (depends on 25)

The composition of claim 25, wherein the polyorthoester is represented by Formula I.

### Claim 34 (depends on 25)

The composition of claim 25, further comprising a protic or an aprotic solvent.

### Claim 35 (depends on 25)

The composition of claim 25, further comprising a triglyceride viscosity reducing agent, wherein the triglyceride viscosity reducing agent comprises three fatty acid groups each independently comprising between 1-7 carbon atoms.

### Claim 36 (depends on 25)

A method for managing pain in a subject in need thereof, comprising: administering to the subject a composition of claim 25.

### Claim 37 (depends on 25)

A method for prophylactic treatment of pain in a subject, comprising: administering to the subject a composition of claim 25.

### Claim 38 (depends on 36)

The method of claim 36, wherein the administering is intramuscular, subcutaneous, perineural or to a wound.

### Claim 39 (depends on 38)

The method of claim 38, wherein the pain is acute pain or chronic pain.

### Claim 40

A composition, comprising: a first therapeutic agent and a delivery vehicle comprised of a polyorthoester, a polar aprotic solvent and a triglyceride viscosity reducing agent, wherein the triglyceride viscosity reducing agent comprises three fatty acid groups each independently comprising between 1-7 carbon atoms.

### Claim 41 (depends on 40)

The composition of claim 40, wherein the composition has a viscosity ranging from about 2500 mPa-s to 10000 mPa-s when measured at 25° C. using a viscometer.

### Claim 42 (depends on 40)

The composition of claim 40, wherein the viscosity of the composition is 10 to 40-fold lower than the viscosity of a similar composition with no triglyceride viscosity reducing agent when measured at 25° C. using a viscometer.

### Claim 43 (depends on 40)

The composition of claim 40, wherein the triglyceride viscosity reducing agent is selected from the group consisting of triacetin and tributyrin.

### Claim 44 (depends on 40)

The composition of claim 40, wherein the polar aprotic solvent is selected from dimethylsulfoxide, N-methyl pyrrolidone and dimethyl acetamide.

### Claim 45 (depends on 40)

The composition of claim 40, wherein the first therapeutic agent is soluble in the triglyceride viscosity reducing agent, the polar aprotic solvent, or a mixture thereof.

### Claim 46 (depends on 40)

The composition of claim 40, wherein the first therapeutic agent is an anesthetic.

### Claim 47 (depends on 40)

The composition of claim 40, wherein the first therapeutic agent is selected from the group consisting of bupivacaine, levobupivacaine, dibucaine, mepivacaine, procaine, lidocaine, tetracaine, and ropivacaine.

### Claim 48 (depends on 40)

The composition of claim 40, wherein the first therapeutic agent is an anti-emetic.

### Claim 49 (depends on 40)

The composition of claim 40, wherein the composition comprises a second therapeutic agent.

### Claim 50 (depends on 49)

The composition of claim 49, wherein the first therapeutic agent is an amide-type local anesthetic and the second therapeutic agent is a non-steroidal anti-inflammatory drug (NSAID).

### Claim 51 (depends on 50)

The composition of claim 50, wherein the first therapeutic agent is selected from the group consisting of bupivacaine, levobupivacaine, dibucaine, mepivacaine, procaine, lidocaine, tetracaine, and ropivacaine.

### Claim 52 (depends on 50)

The composition of claim 50, wherein the NSAID is an enolic-acid NSAID.

### Claim 53 (depends on 52)

The composition of claim 52, wherein the enolic-acid NSAID is selected from the group consisting of meloxicam, piroxicam, tenoxicam, droxicam, lornoxicam, and isoxicam.

### Claim 54 (depends on 50)

The composition of claim 50, wherein the amide-type local anesthetic is bupivacaine or ropivacaine and the enolic-acid NSAID is meloxicam.

### Claim 55 (depends on 54)

The composition of claim 54, wherein the amide-type local anesthetic is present in the composition at between about 0.01 wt % and about 7.5 wt %.

### Claim 56 (depends on 54)

The composition of claim 54, wherein the enolic-acid NSAID is present in an amount above about 0.01 wt % of the composition.

### Claim 57 (depends on 40)

The composition of claim 40, wherein the polyorthoester is selected from the polyorthoesters represented by Formulas I, II, III and IV.

### Claim 58 (depends on 40)

The composition of claim 40, wherein the polyorthoester is represented by Formula I.

### Claim 59 (depends on 40)

The pharmaceutical composition of claim 40, wherein the first therapeutic agent is released from the composition over a time period of about 1 day to about 8 weeks.

### Claim 60 (depends on 40)

A method of treatment, comprising: administering to a patient in need thereof the pharmaceutical composition according to claim 40.

### Claim 61 (depends on 60)

The method according to claim 60, wherein the patient is experiencing pain or is in need of prophylactic treatment for pain and the first therapeutic agent provides pain relief.

### Claim 62 (depends on 61)

The method of claim 61, wherein the pain is acute pain or chronic pain.

### Claim 63 (depends on 60)

The method of claim 60, wherein the administering is intramuscular, subcutaneous, perineural or to a wound.

### Claim 64 (depends on 60)

A method for prophylactic treatment of nausea, comprising: administering to a patient in need thereof the composition according to claim 60, wherein the first therapeutic agent is granisetron.

### Claim 65

A method for extending duration of pain relief of a polyorthoester composition comprising an amide-type local anesthetic, comprising: incorporating in the composition an enolic acid-NSAID in an amount effective to extend the duration of pain relief provided by the composition when compared to a similar composition lacking the effective amount of the enolic acid-NSAID.

### Claim 66 (depends on 65)

The method of claim 65, wherein the enolic acid-NSAID containing composition provides pain relief for a period of time of about 3 days to about 5 days following administration.

### Claim 67 (depends on 65)

The method of claim 65, wherein the amide-type local anesthetic is selected from the group consisting of bupivacaine, levobupivacaine, dibucaine, mepivacaine, procaine, lidocaine, tetracaine, and ropivacaine.

### Claim 68 (depends on 65)

The method of claim 65, wherein the enolic-acid NSAID is selected from the group consisting of meloxicam, piroxicam, tenoxicam, droxicam, lornoxicam, and isoxicam.

### Claim 69 (depends on 65)

The method of claim 65, wherein the amide-type local anesthetic is bupivacaine or ropivacaine and the enolic-acid NSAID is meloxicam.

### Claim 70 (depends on 65)

The method of claim 65, wherein the amide-type local anesthetic is present in the composition at between about 0.01 wt % and about 7.5 wt %.

### Claim 71 (depends on 70)

The method of claim 70, wherein the enolic-acid NSAID is present in an amount above about 0.01 wt % of the composition.

### Claim 72 (depends on 65)

The method of claim 65, wherein the polyorthoester is selected from the polyorthoesters represented by Formulas I, II, III and IV.

### Claim 73 (depends on 65)

The method of claim 65, wherein the polyorthoester is represented by Formula I.

### Claim 74 (depends on 65)

The method of claim 65, further comprising administering the composition to a person in need thereof, whereby said administering provides, as measured in an in vivo model for post-operative pain, an initial decrease in pain relief between about 1 hours and 24 hours after administering and a period of increased pain relief between about 1-3 days after administering, wherein the initial decrease in pain relief is with respect to pain relief provided immediately after administering.

### Claim 75 (depends on 74)

The method of claim 74, wherein the composition provides pain relief over days 2-5 following administration that is at least, on average, about 50% of the average pain relief provided by the composition 1-5 hours post-administration.

### Claim 76 (depends on 65)

The method of claim 65, whereby the administering is effective to provide a measurable plasma concentration of the amide-type local anesthetic and of the NSAID for a period of at least 5 days following administration.

### Claim 77 (depends on 65)

The method of claim 65, wherein about 80% by weight or more of both the local anesthetic and the enolic-acid NSAID are released from the composition over a period of 5 days when measured in an in vitro test at 37° C.

### Claim 78 (depends on 65)

The method of claim 65, wherein the administering is at a nerve, into the epidural space, intrathecal, or directly to a surgical site or wound.

### Claim 79 (depends on 1)

A method for providing pain relief to a patient in need thereof, comprising:
providing a composition according to claim 1, and
instructing that the composition be administered to the patient to provide pain relief for an extended period.

### Claim 80 (depends on 79)

The method of claim 79, wherein the extended period is for at least 5 days.

### Claim 81 (depends on 79)

The method of claim 79, wherein the extended period is for up to 5 days.

### Claim 82 (depends on 79)

The method of claim 79, wherein the extended period is from about 1 day to at least about 5 days.

### Claim 83 (depends on 79)

The method of claim 79, wherein the extended period is for about 3 days.

### Claim 84 (depends on 79)

The method of claim 79, wherein the instructing that the composition be administered comprises instructing that the composition be administered subcutaneously at or near a wound site.

### Claim 85 (depends on 40)

A method for providing pain relief to a patient in need thereof, comprising:
providing a composition according to claim 40, and
instructing that the composition be administered to the patient to provide pain relief for an extended period.
